Here are five things to know:
1. Zimmer is continuing to work with the Bureau of Competition Staff of the U.S. Federal Trade Commission to meet compliance issues for the acquisition.
2. Zimmer hoped to finalize the agreement during the first quarter of 2015, but the company is still moving toward that goal. The most recent news release from Zimmer reports high confidence the deal will be done in the next few weeks.
3. The divestiture agreements are subject to further FTC review and acceptance of a consent order by the Commissioners of the FTC.
4. The European Commission and Japan Fair Trade Commission cleared Zimmer’s proposed acquisition of Biomet.
5. When Zimmer receives the FTC’s consent order and satisfaction of other customary closing conditions, the company plans to close the Biomet merger at the “earliest possible date” — anticipated to be in mid-June.
More articles on orthopedic devices:
Centinel Spine reaches 20k milestone with STALIF C—5 key notes
Invuity sets terms for $60M IPO—7 key notes
MIS SI joint fusion: 5 key notes on NASS coverage recommendation
